Cost-effectiveness of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck.

被引：1
|
作者：
Carroll, Kate
Tringale, Kathryn Ries
Zakeri, Kaveh
Sacco, Assuntina Gesualda
Barnachea, Linda
Murphy, James Don
机构：
[1] Univ Calif San Diego, San Diego Sch Med, Moores Canc Ctr, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Dept Radiat Med & Appl Sci, La Jolla, CA 92093 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.6026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6026
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Tringale, Kathryn R.
    Carroll, Kate T.
    Zakeri, Kaveh
    Sacco, Assuntina G.
    Barnachea, Linda
    Murphy, James D.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05) : 479 - 485
  • [2] Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
    Zargar, Mahdi
    McFarlane, Thomas
    Chan, Kelvin K. W.
    Wong, William W. L.
    [J]. ONCOLOGIST, 2018, 23 (02): : 225 - 233
  • [3] Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
    Yeh, Justin
    Guddati, Achuta Kumar
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (06): : 1821 - 1826
  • [4] Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer
    Ward, Matthew C.
    Shah, Chirag
    Adelstein, David J.
    Geiger, Jessica L.
    Miller, Jacob A.
    Koyfman, Shlomo A.
    Singer, Mendel E.
    [J]. ORAL ONCOLOGY, 2017, 74 : 49 - 55
  • [5] Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis
    Ye D.
    Liang X.
    Chen X.
    Li Y.
    [J]. Scientific Reports, 14 (1)
  • [6] Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis
    Ye, Dongmei
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Yan
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01):
  • [7] Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial
    Xin, Wenxiu
    Ding, Haiying
    Fang, Qilu
    Zheng, Xiaowei
    Tong, Yinghui
    Xu, Gaoqi
    Yang, Guonong
    [J]. BMJ OPEN, 2020, 10 (12):
  • [8] Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States
    Haddad, Robert
    Cohen, Ezra E. W.
    Venkatachalam, Meena
    Young, Kate
    Singh, Prianka
    Shaw, James W.
    Korytowsky, Beata
    Abraham, Pranav
    Harrington, Kevin J.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 442 - 447
  • [9] Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
    Okada, Takuro
    Matsuki, Takashi
    Fushimi, Chihiro
    Okamoto, Isaku
    Sato, Hiroki
    Kondo, Takahito
    Tokashiki, Kunihiko
    Ito, Tatsuya
    Masubuchi, Tatsuo
    Tada, Yuichiro
    Miura, Kouki
    Hanyu, Kenji
    Omura, Go
    Takahashi, Hideki
    Yamashita, Taku
    Oridate, Nobuhiko
    Tsukahara, Kiyoaki
    [J]. ANTICANCER RESEARCH, 2022, 42 (10) : 4907 - 4912
  • [10] Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
    Massarelli, E.
    Lin, H.
    Ginsberg, L. E.
    Tran, H. T.
    Lee, J. J.
    Canales, J. R.
    Williams, M. D.
    Blumenschein, G. R., Jr.
    Lu, C.
    Heymach, J. V.
    Kies, M. S.
    Papadimitrakopoulou, V.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (07) : 1476 - 1480
12345